# Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

> **NCT06120491** · PHASE3 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 1800 (estimated)

## Conditions studied

- Metastatic Castration-Sensitive Prostate Cancer

## Interventions

- **DRUG:** Saruparib
- **DRUG:** Placebo
- **DRUG:** Abiraterone Acetate
- **DRUG:** Darolutamide
- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT06120491
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-21
- **Primary completion:** 2028-01-11
- **Final completion:** 2031-04-30
- **Target enrollment:** 1800 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06120491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06120491, "Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06120491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*